

34. A method according to claim 4 wherein said T cell activator is anti-CD28.

35. A method according to claim 4 wherein said T cell activator is anti-CD2.

36. A method according to claim 4 wherein said T cell activator is staphylococcus enterotoxin B.

37. A method according to claim 13 wherein said T cell activator is anti-CD3.

38. A method according to claim 13 wherein said T cell activator is anti-CD28.

39. A method according to claim 13 wherein said T cell activator is anti-CD2.

40. A method according to claim 13 wherein said T cell activator is staphylococcus enterotoxin B.--

REMARKS

Claims 2-8, 10-17 and newly added claims 29-40 are pending. Claims 1, 9, and 18-28 have been cancelled without prejudice or disclaimer as drawn to a non-elected inventions.

An Appendix of Pending Claims is attached for the Examiner's convenience.

Support for newly added claims 29 and 30 is found on page 15, lines 17-18. Support for newly added claim 31 is found in original claims 2 and 3, and on page 15, lines 17-18. Support for newly added claim 32 is found in original claims 10 and 12, and on page 15, lines 17-18. Support for newly added claims 33-40 is found on page 17, lines 7-11.

Attached hereto is a marked-up version of the changes made to the claims by the "Restriction and Amendment". The attached page is captioned **"Version with markings to show changes made."**

Please direct any calls in connection with this application to the undersigned at (415)

781-1989.

Dated: 7/16/02

Respectfully submitted,

DORSEY & WHITNEY LLP

By: 

Renee M. Kosslak, Reg. No. 47,717 for

Robin M. Silva, Reg. No. 38,304

Filed under 1.34(a)

Four Embarcadero Center - Suite 3400
San Francisco, California 94111-4187
Telephone: (415) 781-1989

1087427.RMK

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"

In the Claims:

Claim 1 has been cancelled.

Claim 2 has been amended as follows:

2. (Amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
 - b) treating said PBMC [cells] with a suppressive-inducing composition for a time sufficient to induce T cell tolerance in said patient; and
 - c) introducing said treated PBMC [cells] to said patient.

Claim 3 has been amended as follows:

3. (Amended) A method according to claim [1 or] 2 wherein said suppressive-inducing composition comprises TGF- β and IL-2.

Claim 4 has been amended as follows:

4. (Amended) A method according to claim [1 or] 2 further comprising treating said donor cells with a T cell activator.

Claim 7 has been amended as follows:

7. (Amended) A method according to claim [1 or] 2 wherein said PBMC[s] are enriched for CD8+ cells.

Claim 8 has been amended as follows:

8. (Amended) A method according to claim [1 or] 2 wherein said PBMC[s] are enriched for CD4+ cells.

Claim 9 has been cancelled.

Claim 10 has been amended as follows:

10. (Amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
 - b) treating said PBMC [cells] with a suppressive-inducing composition for a time sufficient to generate suppressor cells; and
 - c) introducing said suppressor cells to said patient.

11. (Amended) A method according to claim [9 or] 10 wherein said suppressive-inducing composition comprises TGF- β .

12. (Amended) A method according to claim [9 or 20] 10 wherein said suppressive-inducing composition comprises a mixture of IL-2 and TGF- β .

13. (Amended) A method according to claim [9 or] 10 further comprising treating said

donor cells with a T cell activator.

16. (Amended) A method according to claim [9 or] 10 wherein said PBMC[s] are enriched for CD8+ cells.

17. (Amended) A method according to claim [9 or] 10 wherein said PBMC[s] are enriched for CD4+ cells.

Claims 18-28 have been cancelled.

Appendix of Pending Claims

2. (Amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
 - a) removing peripheral blood mononuclear cells (PBMC) from a donor;
 - b) treating said PBMC with a suppressive-inducing composition for a time sufficient to induce T cell tolerance in said patient; and
 - c) introducing said treated PBMC to said patient.
3. (Amended) A method according to claim 2 wherein said suppressive-inducing composition comprises TGF- β and IL-2.
4. (Amended) A method according to claim 2 further comprising treating said donor cells with a T cell activator.
5. A method according to claim 4 wherein said T cell activator is a recipient cell.
6. A method according to claim 2 wherein said method further comprises adding said cells to donor stem cells prior to introduction into said patient.
7. (Amended) A method according to claim 2 wherein said PBMC are enriched for CD8+ cells.
8. (Amended) A method according to claim 2 wherein said PBMC are enriched for CD4+ cells.
10. (Amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
 - a) removing peripheral blood mononuclear cells (PBMC) from a donor;
 - b) treating said PBMC with a suppressive-inducing composition for a time sufficient to generate suppressor cells; and
 - c) introducing said suppressor cells to said patient.
11. (Amended) A method according to claim 10 wherein said suppressive-inducing composition comprises TGF- β .
12. (Amended) A method according to claim 10 wherein said suppressive-inducing composition comprises a mixture of IL-2 and TGF- β .
13. (Amended) A method according to claim 10 further comprising treating said donor cells with a T cell activator.
14. A method according to claim 13 wherein said T cell activator is a recipient cell.
15. A method according to claim 10 wherein said method further comprises adding said cells

to donor stem cells prior to introduction into said patient.

16. (Amended) A method according to claim 10 wherein said PBMC are enriched for CD8+ cells.

17. (Amended) A method according to claim 10 wherein said PBMC are enriched for CD4+ cells.

29. (New) A method according to claim 2 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

30. (New) A method according to claim 10 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

31. (New) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- β and IL-2 for a time sufficient to induce T cell tolerance in said patient; and
- c) introducing said treated CD3+CD4-CD8- cells to said patient.

32. (New) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

33. A method according to claim 4 wherein said T cell activator is anti-CD3.

34. A method according to claim 4 wherein said T cell activator is anti-CD28.

35. A method according to claim 4 wherein said T cell activator is anti-CD2.

36. A method according to claim 4 wherein said T cell activator is staphylococcus enterotoxin B.

37. A method according to claim 13 wherein said T cell activator is anti-CD3.

38. A method according to claim 13 wherein said T cell activator is anti-CD28.

39. A method according to claim 13 wherein said T cell activator is anti-CD2.

40. A method according to claim 13 wherein said T cell activator is staphylococcus enterotoxin B.